Imène Hadji, Medical Oncologist and OncoDaily Hub Lead, shared by Journal of Immunotherapy and Precision Oncology on LinkedIn:
“Now published in the Journal of Immunotherapy and Precision Oncology (JIPO):
‘The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.’
This landmark position paper follows the field of checkpoint inhibition from its early promise through the persistent questions shaping its future – resistance, immune-related adverse events, biomarkers, patient selection, and treatment delivery.
Congratulations to the full author team, including Joud Hajjar, MD, PhD, MS Aung Naing Ajay Sheshadri Zoe Quandt Yinghong (Mimi) Wang Marc-Elie Nader Nagham Al-Zubidi Yu Leo Lei Jean Connors, and all contributing authors.
Follow Journal of Immunotherapy and Precision Oncology for more.
Title: The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact
Authors: Joud Hajjar, Betty Stephen, Ashley E. Aaroe, Mazen M. Aiche, Nagham Al-Zubidi, May Ameri, Kaitlyn E. Aragon, Ivan Darin Carabenciov, Mark S. Chambers, Amina Lateef Chaudhry, Jean M. Connors, Michael A. Davies, Kala Chand Debnath, Saadia A.
Faiz, Clifton D. Fuller, Ryan P. Goepfert, Dan S. Gombos, Shruti Gupta, Matthew Hadfield, Katherine A. Hutcheson, Shajedul Islam, Abdullah Jalal, Migara Jayasekera, Khalid A. Jazieh, Aye Khine, Peter Kim, Stephen Y. Lai, Yu Leo Lei, Yuanteng Jeff Li, Svetomir N. Markovic,
Holly McMillan, Amy C. Moreno, Fiorinda Muhaj, Marc-Elie Nader, Adegbenga Otun, Omar Pacha, Nicolas L. Palaskas, Anisha B. Patel, Nimisha Patel, Zoe Quandt, Oded Sagiv, Elad Sharon, Malek Shatila, Ajay Sheshadri, Maria E. Suarez-Almazor, Anusha Shirwakar Thomas, Yinghong Wang, Alex Won, Hao Chi Zhang, Aung Naing.
Quoting Journal of Immunotherapy and Precision Oncology:
“Hot off the press! In this new JIPO publication, Drs Joud Hajjar, Bettzy Stephen, Aung Naing, and colleagues synthesize key barriers in ICI therapy and highlight emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability.
Together, these advances position the field to move toward a more precise, effective, and patient-centered era of immuno-oncology.
Note: Journal-based CME is available for reading this article via InnoScholar.com